SG Americas Securities
ALNY icon

SG Americas Securities’s Alnylam Pharmaceuticals ALNY Stock Holding History

SG Americas Securities’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-63,000
Closed -$6K – 3255
2016
Q4 		$6K Buy
+63,000
New +$2.64M ﹤0.01% 3037

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

SG Americas Securities's ALNY Position: Q1 2026 in Review

SG Americas Securities reduced its Alnylam Pharmaceuticals (ALNY) stake by 39% in Q1 2026, selling an estimated $12.2M and leaving 55,060 shares worth $18.2M. The position accounts for 0.02% of the portfolio, ranked #578.

SG Americas Securities first reported a position in ALNY in Q3 2013 and has held it in 43 quarters since. The position peaked at $36.2M in Q4 2025. 787 funds tracked by Wall St. Rank hold ALNY as of Q1 2026.

  • SG Americas Securities held 55,060 shares of Alnylam Pharmaceuticals worth $18.2M as of Q1 2026.
  • SG Americas Securities sold 35,861 Alnylam Pharmaceuticals shares in Q1 2026, an estimated $12.2M.
  • Alnylam Pharmaceuticals made up 0.02% of SG Americas Securities's portfolio in Q1 2026, its #578 holding.
  • SG Americas Securities first reported a position in Alnylam Pharmaceuticals in Q3 2013 and has held it in 43 quarters since.
  • SG Americas Securities's Alnylam Pharmaceuticals position peaked at $36.2M in Q4 2025.
  • 787 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2026.

Based on SG Americas Securities's 13F filing for Q1 2026, filed 16 Apr 2026.